



## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant : Zhang, et al.  
App. No. : 10/826,478  
Filed : April 16, 2004  
For : DRUG SCREENING METHOD  
FOR THE TREATMENT OF  
BRAIN DAMAGE  
Examiner : Unknown  
Group Art Unit : 1614

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing seventeen (17) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct. 14, 2004

By: Daniel Hart

Daniel Hart  
Registration No. 40,637  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
WILKG5.001AUSAPPLICATION NO.  
10/826,478SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Zhang, et al.FILING DATE  
April 16, 2004GROUP  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	2003/0050243 A1	03/13/03	Tymianski			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	2	Brenman, et al. 1996. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and $\alpha$ 1-syntrophin mediated by PDZ domains. <i>Cell</i> , 84:757-767.
	3	Chen, et al. 2001. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. <i>Biochemical Pharmacology</i> , 61:1417-1427.
	4	Christopherson, et al. 1999. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. <i>The Journal of Biological Chemistry</i> , 274(39):27467-27473.
	5	Dingledine, et al. 1999. The glutamate receptor ion channels. <i>Pharmacological Reviews</i> , 51(1):7-61.
	6	Fan, et al. 2002. Signaling complex organization by PDZ domain proteins. <i>Neurosignals</i> , 11:315-321.

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. WILKG5.001AUS	APPLICATION NO. 10/826,478
	APPLICANT Zhang, et al.	
	FILING DATE April 16, 2004	GROUP 1614

[illegible]

S:\DOCS\SGJ\SGJ-4432.DOC:dmb  
101304

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	